InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage company headquartered in Cambridge, Massachusetts. The company is publicly traded and employs 13 people. InVivo Therapeutics specializes in the development of biomaterials and biotechnology for the treatment of spinal cord injuries. Their flagship product, the Neuro-Spinal Scaffold™, is an investigational biodegradable device designed to support healing after acute spinal cord injury. The scaffold is implanted at the injury site to minimize cavity formation, protect white matter, and encourage neural regeneration. The Neuro-Spinal Scaffold has received a Humanitarian Use Device designation and is currently being evaluated in a pivotal study called INSPIRE. Founded in 2005, InVivo Therapeutics has earned recognition for its contributions to spinal cord injury medicine, including the David S. Apple Award from the American Spinal Injury Association in 2011 and the Becker’s Healthcare Spine Device Award in 2015. The company's technology is based on co-inventions by renowned scientists Robert Langer and Joseph P. Vacanti. For more information about InVivo Therapeutics and the Neuro-Spinal Scaffold™, visit www.invivotherapeutics.com.